PSMA-PET Guided Radiotherapy

Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · May 14, 2018

Keywords

ClinConnect Summary

This clinical trial, called PSMA-PET Guided Radiotherapy, is exploring a new way to treat prostate cancer. Researchers want to find out if using a specific type of imaging called PSMA-PET can help doctors see cancer spread more clearly than traditional methods like CT scans or bone scans. By using this enhanced imaging to guide radiotherapy (a treatment that uses high-energy rays to kill cancer cells), the goal is to improve outcomes for patients. This trial is currently active but not recruiting new participants.

To be eligible for the trial, participants need to be adults aged 65 to 74 who have been diagnosed with prostate cancer and are planning to receive treatment aimed at curing the disease. They should also be in good overall health and have certain risk factors for cancer spread. Importantly, participants will undergo standard imaging tests before starting the study. If someone joins the trial, they can expect to receive treatment based on the advanced imaging results, which may lead to better control of their cancer. It’s important to note that some individuals, such as those who have had specific treatments recently, might not qualify for the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Enrolled in PERA (CHUM CER 17.0.32) and consented to contact for investigational trials.
• • 2. Histological diagnosis of prostate cancer planned for curative-intent radiotherapy.
• • 3. ECOG 0-1
• • 4. Charlson Cormobidity Index ≤ 4
• 5. High-risk of distant metastases as defined by any of:
• • 1. Oligometastases (≤5) (regional or distant) identified on conventional staging, with ≤ 3 metastasis in any non-bone organ. For a spine metastasis, direct involvement of adjacent spinal segments would still be considered as "one" tumour. For nodal metastases, more than one involved lymph node in the same ipsilateral nodal region/chain would still count as "one" tumour. Defined nodal regions for this protocol include inguinal, external iliac, internal iliac, common iliac, retroperitoneal, hilar/mediastinal, anterior cervical, posterior cervical, and axillary. Metastases in all other organs that are within 1cm of each other will be considered as "one" tumour.
• • 2. Subjects with newly diagnosed high-risk (NCCN) localized prostate cancer and CAPRA score 6-10.
• • 3. Subjects with a prior history of treated prostate cancer (RP or RT), and biochemical failure (Phoenix-RT or\>0.2ng/ml-RP)
• • 6. Standard staging (bone scan, CT pelvis) within 12 weeks of consent.
• Exclusion Criteria:
• • 1. Prior androgen deprivation therapy terminated \< 12 months prior to enrollment.
• • 2. Prior or planned PET scan.